|
From: HCPLive <edigest@HCPLive.com>
Sent: <Day, Month xx, 2020>
To: <<Email address>>
Subject: Making ENTRESTO® Your First Choice
|
|
|
|
|
|
|
FOR YOUR APPROPRIATE PATIENTS WITH SYSTOLIC HEART FAILURE
|
|
|
Time is Essential:
Make ENTRESTO® your first choice
|
|
|
|
|
|
|
|
|
|
|
Join Our Multidisciplinary Expert
|
|
|
Javed Butler, MD, MPH, MBA
Professor and Chairman, Department of Medicine
University of Mississippi
Jackson, MS
|
|
|
|
In this iPub®, Javed Butler, MD, MPH, MBA, will:
|
|
|
|
|
Review the mechanism of action of ENTRESTO® for the management of systolic heart failure
|
|
|
|
|
|
|
Discuss landmark clinical trials in systolic heart failure
|
|
|
|
|
|
|
Review appropriate dosing and access information for ENTRESTO®
|
|
|
|
|
|
|
|
|
|
|
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080
|
|
© 2020 Novartis
9/20 T-HFS-1393918
|
|
|
|
|
|
|
|
|
|
|
HCPLive® – an MJH Life Sciences™ brand
Copyright 2020 © Intellisphere, LLC
2 Clarke Drive | Suite 100 | Cranbury, NJ | 08512
This email contains sponsored advertisements.
Preferences | Unsubscribe
|
|
|
